AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
European Summary of Product Characteristics
AFINITOR® (everolimus) Summary of Product Characteristics — AFINITOR 5 mg tablets (pdf)
AFINITOR® (everolimus) Summary of Product Characteristics — AFINITOR 10 mg tablets (pdf)
Disclaimer: This is an international website for AFINITOR® (everolimus) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
NovartisOncology.com |
About Novartis Oncology |
Contact Us |
Site Map
Use of website is governed by the Terms of Use and Privacy Policy
© 2010 Novartis AG